[go: up one dir, main page]

MX382337B - Terapia génica de globina y uso de la misma para el tratamiento de hemoglobinopatias. - Google Patents

Terapia génica de globina y uso de la misma para el tratamiento de hemoglobinopatias.

Info

Publication number
MX382337B
MX382337B MX2017002900A MX2017002900A MX382337B MX 382337 B MX382337 B MX 382337B MX 2017002900 A MX2017002900 A MX 2017002900A MX 2017002900 A MX2017002900 A MX 2017002900A MX 382337 B MX382337 B MX 382337B
Authority
MX
Mexico
Prior art keywords
globin gene
hemoglobinopathies
treatment
gene therapy
vectors
Prior art date
Application number
MX2017002900A
Other languages
English (en)
Other versions
MX2017002900A (es
Inventor
George Stamatoyannopoulos
Isabelle Riviere
John Stamatoyannopoulos
Jorge Mansilla-Soto
Mingdong Liu
Michel Sadelain
Xiuyan Wang
Original Assignee
Memorial Sloan Kettering Cancer Center
Univ Washington
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Memorial Sloan Kettering Cancer Center, Univ Washington filed Critical Memorial Sloan Kettering Cancer Center
Publication of MX2017002900A publication Critical patent/MX2017002900A/es
Publication of MX382337B publication Critical patent/MX382337B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0066—Manipulation of the nucleic acid to modify its expression pattern, e.g. enhance its duration of expression, achieved by the presence of particular introns in the delivered nucleic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/795—Porphyrin- or corrin-ring-containing peptides
    • C07K14/805—Haemoglobins; Myoglobins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/10041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/15—Vector systems having a special element relevant for transcription chimeric enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/30—Vector systems having a special element relevant for transcription being an enhancer not forming part of the promoter region
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/40—Vector systems having a special element relevant for transcription being an insulator
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/46—Vector systems having a special element relevant for transcription elements influencing chromatin structure, e.g. scaffold/matrix attachment region, methylation free island
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/48—Vector systems having a special element relevant for transcription regulating transport or export of RNA, e.g. RRE, PRE, WPRE, CTE
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/50—Vector systems having a special element relevant for transcription regulating RNA stability, not being an intron, e.g. poly A signal

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención se refiere a cartuchos de expresión que permiten la expresi6n de un gen de globina o una parte funcional de los mismos, vectores que lo comprenden y células transducidas con dichos cartuchos y vectores de expresión; la materia objeto de la presente descripción proporciona además métodos para tratar una hemoglobinopatía en un sujeto que comprende administrar una cantidad eficaz de tales células transducidas al sujeto.
MX2017002900A 2014-09-04 2015-09-04 Terapia génica de globina y uso de la misma para el tratamiento de hemoglobinopatias. MX382337B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462045997P 2014-09-04 2014-09-04
PCT/US2015/048698 WO2016037138A1 (en) 2014-09-04 2015-09-04 Global gene therapy for treating hemoglobinopathies

Publications (2)

Publication Number Publication Date
MX2017002900A MX2017002900A (es) 2017-10-24
MX382337B true MX382337B (es) 2025-03-13

Family

ID=55440425

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017002900A MX382337B (es) 2014-09-04 2015-09-04 Terapia génica de globina y uso de la misma para el tratamiento de hemoglobinopatias.

Country Status (11)

Country Link
US (2) US11717579B2 (es)
EP (3) EP3189143B1 (es)
JP (3) JP6710680B2 (es)
KR (2) KR102500531B1 (es)
CN (3) CN114480393A (es)
AU (2) AU2015311681B2 (es)
BR (1) BR112017004349A2 (es)
CA (1) CA2960209C (es)
ES (1) ES2746529T3 (es)
MX (1) MX382337B (es)
WO (1) WO2016037138A1 (es)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015138852A1 (en) 2014-03-14 2015-09-17 University Of Washington Genomic insulator elements and uses thereof
EP3548617A4 (en) 2016-12-05 2020-06-17 The Regents of The University of California Optimized lentiviral vector for stem cell gene therapy of hemoglobinopathies
TW201839136A (zh) 2017-02-06 2018-11-01 瑞士商諾華公司 治療血色素異常症之組合物及方法
CA3057862A1 (en) * 2017-03-29 2018-10-04 Bluebird Bio, Inc. Vectors and compositions for treating hemoglobinopathies
EP3635120A1 (en) 2017-06-02 2020-04-15 Institut National de la Santé et de la Recherche Médicale (INSERM) Recombinant lentiviral vector for stem cell-based gene therapy of sickle cell disorder
WO2019079437A1 (en) 2017-10-18 2019-04-25 City Of Hope ADENO-ASSOCIATED VIRUS COMPOSITIONS FOR RESTORING THE FUNCTION OF THE HBB GENE AND METHODS OF USE
AU2018378683B2 (en) * 2017-12-06 2025-10-09 Memorial Sloan-Kettering Cancer Center Globin gene therapy for treating hemoglobinopathies
WO2019213011A1 (en) * 2018-04-30 2019-11-07 The Children's Hospital Of Philadelphia Compositions and methods for hemoglobin production
WO2020056400A1 (en) 2018-09-14 2020-03-19 The Children's Hospital Of Philadelphia Compositions and methods for hemoglobin production
AU2019390394C1 (en) * 2018-11-28 2024-11-28 Forty Seven, LLC Genetically modified HSPCs resistant to ablation regime
US20220136007A1 (en) * 2019-02-14 2022-05-05 The Regents Of The University Of California Optimized lentiviral vector compromising minimal enhancer elements for stem cell gene therapy of hemoglobinopathies
EP3931338A4 (en) * 2019-02-28 2023-01-11 The Regents Of The University Of California LENTIVIRAL VECTOR ENHANCEMENT SYSTEMS (CCLC-MGATA/ANK-CORE LCR-BETA-AS3-FB) TO INCREASE EXPRESSION
CN110042124A (zh) * 2019-04-25 2019-07-23 国家卫生健康委科学技术研究所 基因组碱基编辑增加人红细胞中胎儿血红蛋白水平的试剂盒及应用
CN109999053B (zh) * 2019-04-26 2021-03-23 周德旺 曲氟尿苷或曲氟尿苷替匹嘧啶组合物的医药用途
CN110106203B (zh) * 2019-05-24 2023-08-11 中国医学科学院血液病医院（血液学研究所） 一种新型hbb过表达载体及其设计方法和应用
CN110699381A (zh) * 2019-09-17 2020-01-17 合肥瑞灵生物科技有限公司 地中海贫血病基因治疗载体构建方法及其用途
US20220411822A1 (en) * 2020-01-22 2022-12-29 Altius Institute For Biomedical Sciences Novel Erythroid Specific Enhancers and Uses Thereof
JP7031690B2 (ja) * 2020-01-27 2022-03-08 株式会社三洋物産 遊技機
JP2023521410A (ja) * 2020-04-13 2023-05-24 フレッド ハッチンソン キャンサー センター 大型のアデノウイルスペイロードの組み込み
US20240350664A1 (en) * 2020-11-23 2024-10-24 Intas Pharmaceuticals Ltd. Gene therapy based administration of lentivirus vector for treating hemoglobinopathies
US20240209336A1 (en) * 2021-03-31 2024-06-27 Sigilon Therapeutics, Inc. Genetically modified human cell lines and uses thereof
CN113106098B (zh) * 2021-04-21 2022-04-01 贵州医科大学 一种在红系细胞中特异表达人β珠蛋白的重组序列及其应用
CN113564248A (zh) * 2021-09-26 2021-10-29 北京贝瑞和康生物技术有限公司 同时检测hba1/2、hbb和hbd基因位点多种突变的方法和试剂盒
CN114457119B (zh) * 2022-04-11 2022-08-12 中吉智药(南京)生物技术有限公司 慢病毒载体在制备治疗β-地中海贫血药物中的应用
WO2024186677A2 (en) * 2023-03-03 2024-09-12 Altius Institute For Biomedical Sciences Dna binding proteins for regulating hemoglobin expression
CN116271106B (zh) * 2023-05-24 2023-08-11 中吉智药(南京)生物技术有限公司 慢病毒载体LentilAlpha在制备治疗α-地中海贫血药物中的应用
WO2025151744A1 (en) 2024-01-10 2025-07-17 University Of Tennessee Research Foundation Improved globin and other lentiviral vectors for gene therapy
CN118006803B (zh) * 2024-03-21 2025-02-14 西北农林科技大学 一种与绵羊高海拔适应相关的分子标记及其应用

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4873192A (en) 1987-02-17 1989-10-10 The United States Of America As Represented By The Department Of Health And Human Services Process for site specific mutagenesis without phenotypic selection
US5399346A (en) 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
US5725871A (en) 1989-08-18 1998-03-10 Danbiosyst Uk Limited Drug delivery compositions comprising lysophosphoglycerolipid
US5707644A (en) 1989-11-04 1998-01-13 Danbiosyst Uk Limited Small particle compositions for intranasal drug delivery
US5399363A (en) 1991-01-25 1995-03-21 Eastman Kodak Company Surface modified anticancer nanoparticles
US5756353A (en) 1991-12-17 1998-05-26 The Regents Of The University Of California Expression of cloned genes in the lung by aerosol-and liposome-based delivery
ES2105262T3 (es) 1992-05-18 1997-10-16 Minnesota Mining & Mfg Dispositivo de suministro de farmaco a traves de las mucosas.
US5543158A (en) 1993-07-23 1996-08-06 Massachusetts Institute Of Technology Biodegradable injectable nanoparticles
IE80468B1 (en) 1995-04-04 1998-07-29 Elan Corp Plc Controlled release biodegradable nanoparticles containing insulin
IL178921A0 (en) 1998-12-24 2007-03-08 Yeda Res & Dev Caspase-8 interacting proteins
CA2451173C (en) 2001-06-29 2012-12-18 Sloan Kettering Institute For Cancer Research Vector encoding human globlin gene and use thereof in treatment of hemoglobinopathies
AU2003276494A1 (en) * 2002-06-13 2004-01-23 Regulome Corporation Functional sites
US20080069805A1 (en) * 2005-05-18 2008-03-20 Williams Bruce M Use of stem cells to cure genetic diseases in humans cure for sickle cell anemia
US9018011B2 (en) * 2007-02-15 2015-04-28 The United States As Represented By The Secretary Of The Department Of Health And Human Services Gamma satellite insulator sequences and their use in preventing gene silencing
US8790345B2 (en) 2007-08-21 2014-07-29 Zimmer, Inc. Titanium alloy with oxidized zirconium for a prosthetic implant
US20090156534A1 (en) * 2007-09-13 2009-06-18 Memorial Sloan-Kettering Cancer Center Globin lentiviral vectors for treatment of disease
WO2010046493A2 (en) * 2008-10-23 2010-04-29 Université de Lausanne Gene transfer vectors comprising at least one isolated dna molecule having insulator and or boundary properties and methods to identify the same
WO2010113037A1 (en) * 2009-04-03 2010-10-07 Centre National De La Recherche Scientifique Gene transfer vectors comprising genetic insulator elements and methods to identify genetic insulator elements
CA2798988C (en) 2010-05-17 2020-03-10 Sangamo Biosciences, Inc. Tal-effector (tale) dna-binding polypeptides and uses thereof
CN104737430B (zh) * 2012-08-03 2018-01-02 Abb 技术有限公司 峰值功率操作中的过载限制
WO2014026110A2 (en) * 2012-08-10 2014-02-13 Bluebird Bio, Inc. Compounds for improved viral transduction
US8823480B2 (en) * 2012-08-10 2014-09-02 Tyco Electronics Corporation Planar electronic device
US20150224209A1 (en) * 2012-09-14 2015-08-13 The Regents Of The University Of California Lentiviral vector for stem cell gene therapy of sickle cell disease
ES2747817T3 (es) * 2014-01-30 2020-03-11 Childrens Hospital Med Ct Una hemoglobina fetal mejorada para la corrección génica de la anemia falciforme
WO2015138852A1 (en) * 2014-03-14 2015-09-17 University Of Washington Genomic insulator elements and uses thereof

Also Published As

Publication number Publication date
EP3189143A1 (en) 2017-07-12
JP2020079327A (ja) 2020-05-28
WO2016037138A8 (en) 2017-03-16
ES2746529T3 (es) 2020-03-06
CN114457076A (zh) 2022-05-10
AU2021290257A1 (en) 2022-01-27
CA2960209A1 (en) 2016-03-10
US11717579B2 (en) 2023-08-08
EP3620521A1 (en) 2020-03-11
JP7158427B2 (ja) 2022-10-21
JP6710680B2 (ja) 2020-06-17
JP2022107736A (ja) 2022-07-22
AU2015311681A1 (en) 2017-04-13
MX2017002900A (es) 2017-10-24
AU2015311681A8 (en) 2019-08-08
EP3189143B1 (en) 2019-08-07
CA2960209C (en) 2023-08-29
JP2017532023A (ja) 2017-11-02
AU2015311681B2 (en) 2021-09-23
AU2021290257B2 (en) 2025-08-21
US20170173185A1 (en) 2017-06-22
EP4438115A2 (en) 2024-10-02
KR102500531B1 (ko) 2023-02-17
CN107208093B (zh) 2022-03-01
EP3620521B1 (en) 2024-05-29
BR112017004349A2 (pt) 2017-12-05
US20240066148A1 (en) 2024-02-29
WO2016037138A1 (en) 2016-03-10
EP3189143A4 (en) 2018-03-21
KR20230030002A (ko) 2023-03-03
CN107208093A (zh) 2017-09-26
KR20170044752A (ko) 2017-04-25
EP4438115A3 (en) 2025-01-08
CN114480393A (zh) 2022-05-13

Similar Documents

Publication Publication Date Title
MX382337B (es) Terapia génica de globina y uso de la misma para el tratamiento de hemoglobinopatias.
MY183703A (en) Oncolytic adenovirus encoding a b7 protein
IL268554A (en) Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer
BR112017005598A2 (pt) macrociclos peptidomiméticos e usos dos mesmos
MX2023000050A (es) Metodos de acondicionamiento de pacientes para tratamiento con linfocitos t.
CL2017000515A1 (es) Cd123 agentes enlazadores y su uso
MX378273B (es) Compuestos activos hacia bromodominios.
NZ782095A (en) Materials and methods for treatment of titin-based myopathies and other titinopathies
PE20180673A1 (es) Tratamiento contra el cancer por manipulacion de la microflora comensal
MX388380B (es) Composiciones para usarse en el incremento de los niveles de glóbulos rojos y el tratamiento de enfermedad de células falciformes.
BR112018008503A2 (pt) método para tratar câncer de pulmão de células pequenas, método para tratar um sujeito, método para selecionar um sujeito com câncer
EA201691866A1 (ru) Проникающие в опухоль лимфоциты для адоптивной клеточной терапии
EA201591674A1 (ru) Противораковые вакцины и способы лечения с их применением
EA201791007A3 (ru) Соединения и их применения для модуляции гемоглобина
EA201591432A1 (ru) Соединения и их применения для модуляции гемоглобина
AR101312A1 (es) Combinaciones de inhibidores de bet e inhibidores de tirosina quinasa de bruton
AR101072A1 (es) Extracto de fermento de una cepa bacteriana para el aumento de los niveles de adiponectina
BR112015023439A2 (pt) combinação de tratamentos de câncer utilizando micrornas e inibidores egfr-tki
BR112015030356A2 (pt) métodos de tratamento de uma taupatia
MX2021013354A (es) Metodos para tratar y/o prevenir queratosis actinica.
BR112017011685A2 (pt) composições compreendendo 15-hepe e métodos de tratamento ou prevenção da fibrose usando as mesmas
BR112016015997A2 (pt) ?composições farmacêuticas que compreendem 15- hepe e métodos para tratar asma e distúrbios pulmonares com o uso das mesmas?
CL2018001104A1 (es) Composición para el cuidado de la piel y procedimiento asociado.
MX2018002816A (es) Metodos de tratamiento de mieloma multiple y leucemia de celulas plasmaticas mediante terapia de celulas t.
PH12019550033A1 (en) Treatment of non-hodgkin lymphoma using lilotomab and 177lu-lilotomab satetraxetan